GNR-084
/ Generium
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
March 06, 2024
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
(clinicaltrials.gov)
- P1/2 | N=36 | Recruiting | Sponsor: AO GENERIUM | Trial completion date: Jun 2024 ➔ Jun 2025 | Trial primary completion date: Dec 2023 ➔ Feb 2025
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology
February 24, 2023
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
(clinicaltrials.gov)
- P1/2 | N=36 | Recruiting | Sponsor: AO GENERIUM | Trial completion date: Jun 2023 ➔ Jun 2024 | Trial primary completion date: Jun 2023 ➔ Dec 2023
Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CCR7 • CD19 • CD20 • PTPRC
October 26, 2021
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
(clinicaltrials.gov)
- P1/2; N=36; Recruiting; Sponsor: AO GENERIUM; Trial primary completion date: Jun 2021 ➔ Jun 2023
Clinical • Trial primary completion date • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • CCR7 • CD19 • CD20 • PTPRC
October 26, 2020
GNR-084 Safety and Pharmacological Characteristics in Refractory or Relapse B-cell Precursor ALL
(clinicaltrials.gov)
- P1/2; N=36; Recruiting; Sponsor: AO GENERIUM
Clinical • New P1/2 trial • Acute Lymphocytic Leukemia • Hematological Malignancies • Leukemia • Oncology
1 to 4
Of
4
Go to page
1